Physical and occupational therapy may be beneficial for some patients. Alterations in diet may provide temporary improvement but will not alter the course of the disease. Genetic counseling can provide families with information regarding risk in future pregnancies.On April 28, 2006, the US Food and Drug Administration approved a Biologic License Application (BLA) for alglucosidase alfa, rhGAA (Myozyme), the first treatment for patients with Pompe disease, developed by a team of Duke University researchers. This was based on enzyme replacement therapy using biologically active recombinant human alglucosidase alfa produced in Chinese Hamster Ovary cells. Myozyme falls under the FDA Orphan Drug designation and was approved under a priority review.The FDA has approved Myozyme for administration by intravenous infusion of the solution. The safety and efficacy of Myozyme were assessed in two separate clinical trials in 39 infantile-onset patients with Pompe disease ranging in age from 1 month to 3.5 years at the time of the first infusion. Myozyme treatment clearly prolongs ventilator-free survival and overall survival. Early diagnosis and early treatment leads to much better outcomes. The treatment is not without side effects which include fever, flushing, skin rash, increased heart rate and even shock; these conditions, however, are usually manageable.Myozyme costs an average of US$300,000 a year and must be taken for the patients entire life, so some American insurers have refused to pay for it. On August 14, 2006, Health Canada approved Myozyme for the treatment of Pompe disease.
DTaP-IPV/Hib vaccine is a 5-in-1 combination vaccine that protects against diphtheria, tetanus, whooping cough, polio, and Haemophilus influenzae type B.Its generic name is diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus B conjugate vaccine, and it is also known as DTaP-IPV-Hib. Uses
DTaP-IPV/Hib vaccine is administered to young children to immunise against diphtheria, tetanus, pertussis, poliomyelitis, and diseases caused by Haemophilus influenzae type B.

Formulations
A branded formulation marketed in the United States is Pentacel, manufactured by Sanofi Pasteur.Pentacel is known in the UK and Canada as Pediacel.An equivalent vaccine marketed in the UK and Canada by GlaxoSmithKline is Infanrix IPV + Hib. This is a two-part vaccine. The DTaP-IPV component is supplied as a sterile liquid, which is used to reconstitute lyophilized (freeze-dried) Hib vaccine. Pentaxim is a liquid formulation marketed by Sanofi Pasteur. Availability
It is only licensed for young children. In the US the FDA have approved the vaccine for children from age 6 weeks up to age 5 years. It was used in the UK until 2017, following which a 6-in-1 vaccine became available containing the additional protection against Hepatitis B. == References ==